10 Nov
2022
02:30 E.S.T.

Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)

Read more

03 Nov
2022
16:05 E.S.T.

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Read more

03 Nov
2022
13:43 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022

Read more

27 Oct
2022
16:30 E.S.T.

Cellectis to Report Third Quarter 2022 Financial Results

Read more

11 Oct
2022
16:30 E.S.T.

Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022

Read more

05 Oct
2022
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Read more

28 Sep
2022
16:25 E.S.T.

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer

Read more

01 Sep
2022
16:30 E.S.T.

Cellectis Announces Participation in Four Upcoming Investor Conferences in September

Read more

04 Aug
2022
16:30 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

Read more

01 Aug
2022
16:30 E.S.T.

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

Read more